President Trump just added nine more drug companies to his prescription pricing program, bringing the total to 26 manufacturers. Here’s what actually changes, what stays the same, and how to check whether your own prescription gets cheaper.
Trump Announces New Drug Pricing Deals — Will You Pay Less?
Trump’s New Drug Pricing Deals: What Changes and What Doesn’t
President Trump has announced drug pricing agreements with nine more pharmaceutical companies. The White House says that brings the total to 26 manufacturers, covering 89% of the branded drug market.
That sounds like a sweeping price cut. But the biggest question for your budget isn’t how many companies signed. It’s whether your specific prescription, insurance plan, and pharmacy will actually leave you paying less.
What Changed
The nine new companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. Their agreements are built around “most favored nation” pricing, usually shortened to MFN.
In simple terms, the government wants prices available in the United States to line up with the lower prices these same drugmakers already accept in other developed countries.
There’s a real price gap behind that argument. A 2024 RAND study using 2022 data found that American prescription drug prices averaged 2.78 times prices in 33 comparison countries. For brand name originator drugs, the gap was 4.22 times before rebates. Even after adjusting for rebates, American brand prices remained more than three times as high.
Key Details: Medicaid Is the Immediate Focus
For the nine new agreements, the clearest immediate focus is Medicaid. The White House says every state Medicaid program will have access to MFN prices on products made by these companies. The affected medicines cover costly conditions such as cancer, Parkinson’s disease, hemophilia, glaucoma, liver disease, and serious skin conditions.
But this is where the headline and your household experience can separate. Medicaid already receives substantial manufacturer rebates under federal law, and beneficiaries usually face limited prescription cost sharing. A lower net price could save federal and state budgets real money without changing a beneficiary’s small copay very much.
Imagine a medicine has a high public list price, but Medicaid already gets a large rebate and the patient pays only a modest copay. A new agreement might push the government’s net cost lower — helping taxpayers and giving a state more room in its health budget — but it doesn’t mean the patient sees the entire difference at the counter.
Important Dates: The Program Is Voluntary
The Medicaid mechanism is voluntary on both sides. CMS says its GENEROUS model began in January 2026 and is designed to run for five years. Participating manufacturers provide supplemental rebates intended to align Medicaid net prices with prices in selected countries, and states choose whether to participate. CMS currently gives states until September 10, 2026 to apply.
That means implementation matters as much as the Oval Office announcement. Patients still need to know which product is included, whether their state participates, when the price takes effect, and how their plan handles the prescription. The public announcement names disease categories — it doesn’t hand every patient a drug-by-drug price sheet with an individual savings amount.
Why One Medicine Can Have Several Different Prices
One reason this gets confusing is that a single medicine can carry several prices at the same time: the manufacturer’s list price, a lower net price after rebates, a price negotiated by an insurer, a Medicaid price, and sometimes a separate cash price.
Two people can pick up the same medicine at the same pharmacy and owe different amounts because their coverage, deductible, and assistance eligibility differ. So a claim that “a drug price fell” can be true even when one patient’s receipt hasn’t changed at all.
TrumpRx and Direct Cash Prices
There’s another route that may be more visible to some households. TrumpRx.gov launched in February 2026 as a way to connect patients with discounted direct-purchase options from manufacturers and participating sellers. The White House says patients have saved more than $700 million through the platform since launch — an administration-reported total that doesn’t tell you whether the cash price beats your own insurance price.
Suppose your insurance copay is $60, while a direct purchase offer is $45. The cash option looks better by $15 today. But before changing how you pay, check whether the cash purchase counts toward your deductible or annual out-of-pocket limit, and compare the same medication, dose, quantity, and refill period. A lower-looking number can be misleading when the package or rules are different.
Beyond the Pharmacy Counter
The agreements extend past the pharmacy. The nine companies pledged at least $19.6 billion in near-term American manufacturing investment. Several also promised active pharmaceutical ingredients for a strategic reserve, including ingredients used in seizure medicine, antibiotics, blood pressure medicine, and transplant care. Those commitments are about supply security and domestic production — not an instant reduction in your copay.
The White House estimates its overall MFN agreements could produce $600 billion in savings over ten years. Treat that as a projection, not money already saved. The actual result will depend on participation, which drugs are covered, the prices used for comparison, prescription volume, and how much of any reduction reaches governments, insurers, employers, and patients.
Coverage through an employer adds another layer. The new announcement is centered on Medicaid and doesn’t automatically rewrite every employer health plan. An employer plan may negotiate through an insurer or pharmacy benefit manager, set its own formulary, and divide costs through deductibles, copays, or coinsurance. Lower manufacturer prices could eventually influence those arrangements, but the announcement alone doesn’t promise an immediate cut for every worker or family.
What This Means for You
If you take an expensive brand-name medicine, start by searching for the exact drug and dose on TrumpRx and on the manufacturer’s assistance or direct-purchase page. Then compare that price with your insurance copay and with a reputable pharmacy price for the same quantity. Ask your insurer or pharmacist whether paying cash changes how the purchase counts toward your deductible or out-of-pocket maximum.
If you’re covered by Medicaid, check your state program or managed care plan rather than assuming the announcement already changed your price. Ask whether the medicine is covered, whether prior authorization is required, and whether a preferred alternative exists.
Common Mistakes to Avoid
Don’t stop treatment or switch medicines based only on a headline price — a prescriber or pharmacist should help you compare medically appropriate options. And don’t assume 89% market coverage means an 89% discount on your specific prescription; the announcement covers which companies signed on, not what any one patient will pay.
It also helps to keep a simple record when you refill an expensive medicine: the date, quantity, insurance payment, your payment, and any coupon or direct-purchase price you considered. That gives you a clean comparison when a new program starts or your plan changes. If the amount rises unexpectedly, ask the pharmacy whether the claim used the same plan and whether a coverage rule changed before assuming the drug itself became more expensive.
Frequently Asked Questions
Will my prescription actually cost less because of this deal?
Maybe, but it isn’t automatic. It depends on the specific drug, whether your state’s Medicaid program participates, and whether you have Medicaid, employer insurance, or another type of coverage. The safest step is to check TrumpRx, your plan, and your pharmacist directly rather than assuming a lower price applies to you.
Which companies are part of the new agreements?
The nine newest companies are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, bringing the total to 26 manufacturers with MFN agreements.
Does this lower prices for people with employer health insurance?
Not directly. These agreements are centered on Medicaid. An employer plan negotiates its own prices through an insurer or pharmacy benefit manager, so this announcement doesn’t automatically change what you pay through work-based coverage.
What is TrumpRx and how do I use it?
TrumpRx.gov is a government website launched in February 2026 that connects patients with discounted direct-purchase options from manufacturers. Search for your exact medication and dose there, then compare the price to your insurance copay before deciding how to pay.
Why would a “lower price” not show up on my receipt?
A medicine can have several prices at once — list price, net price after rebates, an insurer-negotiated price, a Medicaid price, and a cash price. A deal that lowers the government’s net cost doesn’t automatically change every one of those other prices, including the one on your receipt.
Is the $600 billion in savings guaranteed?
No. That figure is a White House projection over ten years, not money that has already been saved. The real result depends on participation, which drugs are covered, and how much of any reduction reaches patients rather than governments, insurers, or employers.
Key Takeaway
The central idea is promising, and the target is real: Americans have paid far more for many branded medicines than patients in comparable countries. But 89% market coverage is not the same as 89% off your prescription bill.
Watch for effective dates and published results rather than the size of the announcement. A press release can establish a commitment; it can’t by itself show what your household saved. The deal matters when the lower number reaches the person holding the receipt.
Money Instructor provides educational information only and does not offer medical, insurance, or financial advice. Prescription drug prices, program rules, and government estimates may change. Please verify current details with official sources such as Medicaid.gov, CMS.gov, or TrumpRx.gov, and consult your insurer, pharmacist, or prescriber before making decisions about your medications or coverage.